AB 1178: Dietary supplements: labeling: live microorganisms.
- Session Year: 2019-2020
- House: Assembly
- Latest Version Date: 2019-06-03
|
Date
|
Status
|
|---|---|
| Aug 30, 2019 | In committee: Held under submission. |
| Aug 12, 2019 | In committee: Referred to APPR. suspense file. |
| Jul 5, 2019 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 7. Noes 0.) (July 3). Re-referred to Com. on APPR. |
| Jun 3, 2019 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| May 1, 2019 | Referred to Com. on HEALTH. |
| Apr 23, 2019 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Apr 22, 2019 | Read third time. Passed. Ordered to the Senate. |
| Apr 11, 2019 | Read second time. Ordered to third reading. |
| Apr 10, 2019 | From committee: Do pass. (Ayes 17. Noes 0.) (April 10). |
| Apr 3, 2019 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 14. Noes 1.) (April 2). Re-referred to Com. on APPR. |
| Mar 28, 2019 | Re-referred to Com. on HEALTH. |
| Mar 27, 2019 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Mar 11, 2019 | Referred to Com. on HEALTH. |
| Feb 22, 2019 | From printer. May be heard in committee March 24. |
| Feb 21, 2019 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 12, 2019 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jul 3, 2019 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| Apr 22, 2019 | AB 1178 Quirk Assembly Third Reading | Assembly Floor |
Passed |
|
| Apr 10, 2019 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 2, 2019 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
SENATE COMMITTEE ON
Senator Anthony Portantino, Chair
2019 - 2020 Regular Session
AB 1178 (Quirk) - Dietary supplements: labeling: live microorganisms
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
Assembly Bill 1178, would require, effective January 1, 2022, a manufacturer or distributor of dietary supplements, as defined in federal law, to include the genus, species, and strain of each live organism on the label of the dietary supplement that contains live microorganisms and is sold in the state.
Fiscal Impact:
- No fiscal impact to the Department of Public Health (CDPH), which enforces the Sherman Act.
- Staff anticipates unknown, potentially significant ongoing costs (high-tens of thousands to low hundreds of thousands General Fund) for the Department of Justice’s increased investigation and enforcement workload under the Unfair Competition Law, which also borrows from Health and Safety Code provisions, and minor costs to update the master table and notification materials to the public. While the department indicates a resource need for 1.0 Deputy Attorney General and 1.0 Legal Secretary at this time, there is a degree of uncertainty as to the volume of cases that would arise as a result of the bill. Absent more specific information on the total number of products currently on the market that would qualify under the bill’s provisions, as well as the reporting process of a manufacturer or distributor, staffing needs should be evaluated within the context of the annual budget.
Background:
The U.S. Food and Drug Administration (FDA) enforces various requirements for food labels, including the Nutritional Labeling and Education Act and the Food Allergen Labeling and Consumer Protection Act. The CDPH enforces the Sherman Food, Drug, and Cosmetic Law, which requires that food is not adulterated, misbranded, or falsely advertised, and the Dietary Supplement Good Manufacturing Practices Act. The California Code of Regulations defines “dietary supplement” contains specified dietary ingredients, and is intended to be ingested in a pill, capsule, tablet or liquid form, and is not represented for use as a conventional food or as the sole item of a meal or diet. Dietary Supplements must be labeled according to the federal Dietary Supplement Health and Education Act (DSHEA). Under DSHEA, a dietary supplement can make certain structure function claims, but cannot be sold for the treatment, prevention, mitigation, or cure of diseases or conditions associated with known diseases. Such claims render the products unapproved drugs, and it is illegal to manufacture and sell unapproved drugs. In addition, California has specific regulations that require a warning statement on the labels of dietary supplements that contain stimulant laxative ingredients, such as senna, cascara sagrada, aloe latex, buckthorn, frangula, and rhubarb root. Existing law provides the following fine levels for violations of law pertaining to dietary supplement labeling: $1,000 for the first violation, $2,000 for the second, and $5,000 for the third and each subsequent violation.
The author is proposing the measure for consumer awareness regarding the types of live microorganisms contained in probiotic products.
Proposed Law:
Assembly Bill 1178, would require, effective January 1, 2022, a manufacturer or distributor of dietary supplements, as defined in federal law, to include the genus, species, and strain of each live organism on the label of the dietary supplement that contains live microorganisms and is sold in the state.
Staff Comments:
The actual impact will depend on numerous factors, including, but not limited to, the frequency with which non-compliance is reported, if parties settle matters prior to litigation, and the factors unique to each case.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Richard Pan, Chair
BILL NO: AB 1178
AUTHOR: | Quirk | ||
VERSION: | June 3, 2019 | ||
HEARING DATE: | July 3, 2019 | ||
CONSULTANT: | Vincent D. Marchand | ||
SUBJECT: Dietary supplements: labeling: live microorganisms
SUMMARY:
Requires a manufacturer or distributor of dietary supplements that contain live microorganisms, to include the genus, species, and strain of each live microorganism in the dietary supplement on the label of the dietary supplement, commencing January 1, 2022.
Existing state law:
- Enacts the Sherman Food, Drug and Cosmetic Law, enforced by the Department of Public Health (DPH), which provides broad authority for DPH to enforce food safety requirements, including that food is not adulterated, misbranded, or falsely advertised. Food labeling requirements generally adopt federal food labeling laws as the state requirement, including nutrition labeling and allergen labeling, but DPH is permitted, by regulation, to adopt additional food labeling regulations. [HSC §109875, et seq,, HSC §110100]
- Requires, whenever a warning label is included on any product defined as a dietary supplement pursuant to federal law, the label to be clear and conspicuous. [HSC §110422]
- Establishes fines for violations of provisions of law pertaining to dietary supplement labeling of $1,000 for the first violation, $2,000 for the second violation, and $5,000 for the third and each subsequent violation. [HSC §110422.5]
Existing federal law:
- Establishes, through the U.S. Food and Drug Administration (FDA), various requirements for food labels under the Federal Food, Drug, and Cosmetic Act (FD&C Act), which includes the Nutritional Labeling and Education Act and the Food Allergen Labeling and Consumer Protection Act. These include requiring specified nutrition information, a listing of all ingredients, and whether a produce contains any of eight major food allergens, such as milk, eggs, shellfish, tree nuts, etc. [21 USC §301, et seq., 21 CFR §101, et seq.],
- Defines “dietary supplement” as a product intended to supplement the diet that bears or contains one or more of the following dietary ingredients: a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance to supplement the diet by increasing the total dietary intake; or, a concentrate, metabolite, constituent, extract, or combination of any of these ingredients. Excludes from this definition something that is represented for use as a conventional food or as a sole item of a meal or the diet. [21 USC §322(ff)]
This bill:
- Requires a manufacturer or distributor of dietary supplements, as defined in specified federal law, that contain live microorganisms, to include the genus, species, and strain of each live microorganism in the dietary supplement on the label of the dietary supplement, commencing January 1, 2022.
- Prohibits the labeling requirement in this bill from applying to dietary supplements containing live microorganisms manufactured before July 1, 2021, that are sold prior to January 1, 2023.
- Specifies that this bill does not in any way limit or restrict any rights, remedies, or duties otherwise applicable by law.
- Requires this bill to be implemented to the extent permitted by federal law.
PRIOR VOTES:
Assembly Floor: | 74 - 1 |
Assembly Appropriations Committee: | 17 - 0 |
Assembly Health Committee: | 14 - 1 |
FISCAL EFFECT:
According to the Assembly Appropriations Committee, any impact to DPH to enforce the labeling requirement is expected to be minor and absorbable (Food Safety Fund).
COMMENTS:
- Author’s statement. According to the author, operating under limited federal guidance, manufacturers of dietary supplements containing live microorganisms, also known as over-the-counter (OTC) probiotics, currently label live microorganisms using varying levels of specificity. However, because different microbial strains can have different effects, strain-level identification is important for substantiating claims and ensuring the integrity of a probiotic. We cannot expect manufacturers to label their products consistently without providing standardization.
- FDA regulation of dietary supplements. The FD&C Act requires that manufacturers and distributors who wish to market dietary supplements that contain a “new dietary ingredient” (NDI) to notify the FDA about these ingredients. An NDI is an ingredient that was not marketed in a dietary supplement in the United States prior to October 15, 1994. When notifying the FDA about an NDI, the notification must include information that is the basis on which the manufacturer or distributor has concluded that a dietary supplement containing the NDI will reasonably be expected to be safe under the conditions of use recommended or suggested in the labeling. While FDA is not required to formally approve an NDI, it will consider a dietary supplement “adulterated” unless the NDI has been present in the food supply in the same chemical form that you plan to use in the dietary supplement, or the manufacturer has shown evidence of safety at least 75 days before being introduced or delivered for introduction into interstate commerce, including any citation to published articles.
- Background on probiotics. According to the National Center for Complementary and Integrative Health, part of the National Institutes of Health, probiotics are live microorganisms that are intended to have health benefits. Probiotics may: help maintain a desirable community of microorganisms; stabilize the digestive tract’s barriers against undesirable microorganisms; help microorganisms in the digestive tract return to normal after being disturbed by the use of an antibiotic or a disease; outcompete undesirable microorganisms; and, stimulate the immune response. Products sold as probiotics include foods (such as yogurt), dietary supplements, and products that aren’t used orally, such as skin creams. Although people often think of bacteria and other microorganisms as harmful “germs,” many microorganisms help our bodies function properly, and that many of the microorganisms in probiotic products are the same as or similar to microorganisms that naturally live in our bodies. There is preliminary evidence that some probiotics are helpful in preventing diarrhea caused by infections and antibiotics and in improving symptoms of irritable bowel syndrome, but more needs to be learned. We still don’t know which probiotics are helpful, or who would most likely benefit from taking probiotics. Although some probiotics have shown promise in research studies, strong scientific evidence to support specific uses of probiotics for most health conditions is lacking. Some experts have cautioned that the rapid growth in marketing and use of probiotics may have outpaced scientific research for many of their proposed uses and benefits.
- Prior legislation. AB 954 (Chiu, Chapter 787, Statutes of 2017) requires the Department of Food and Agriculture, in consultation with DPH, to publish information by July 1, 2018 that encourages food manufacturers, processors, and retailers to voluntarily use specified “best by” and “use by” labels that communicate quality and safety dates, respectively.
SB 1381 (Evans of 2014) would have enacted “The California Right to Know Genetically Engineered Food Act” to require the labeling of all genetically engineered foods sold within California. SB 1381 failed passage on the Senate Floor. - Support. The California Medical Association (CMA) states in support that probiotics have experienced a four-fold increase in usage between 2007 and 2012, with a U.S. market that is expected to reach $6.5 billion by 2023. According to CMA, although consumers have typically considered probiotics to be beneficial, there is growing scientific evidence that probiotics may have unanticipated, dangerous side-effects, raising broad questions about their presumed safety. One of the biggest challenges to assessing the safety of dietary supplements containing live microorganisms is that there are no current guidelines as to how the microorganisms should be labeled. CMA states this bill will address this deficiency and provide for the truth and transparency in labeling that CMA has consistently supported. The International Food Additives Council also supports this bill, stating that the information on genus, species, and strain of the live microorganism is information that is already available from the manufacturer and poses limited barriers for the industry to comply.
- Letter of interest. The International Scientific Association for Prebiotics and Probiotics (ISAPP) states that it is a non-profit organization incorporated in California dedicated to advancing the science of probiotics and prebiotics. ISAPP states that it supports this bill in principle, but has some concerns about implementation of the requirement for naming strains. ISAPP expects that subsequent regulations would assure that Latin names (genus, species and subspecies) used on labels would conform to names recognized by taxonomic authorities to the extent practicable. Official changes in bacterial nomenclature are not uncommon, and this presents a challenge for manufacturers. Further, ISAPP is concerned about a possible unintended negative consequence of requiring the labeling of strains. It is possible that product manufacturers comply but do so using strain names that are not traceable. According to ISAPP, whereas genus and species names are validated through scientific committees, there are no scientific requirements or conventions for naming strains. Therefore, if a company does not wish to disclose the strains in its product, it could conceivable just make up a strain designation. This has the potential to be more confusing to the end user. Although ISAPP agrees that responsible companies should label the strains in their products, because we can’t assure that traceable strain designations will be used, it may not achieve the intended result. SAPP questions if a state law is the best way to improve transparency, as a patchwork of state laws may make compliance untenable nationwide. ISAPP suggests voluntary industry standards or federal regulations may be more suitable.
SUPPORT AND OPPOSITION:
Support: California Medical Association
International Food Additives Council
Oppose: None received
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1178
Author:(Quirk)
As Amended Ver:March 27, 2019
Majority vote
SUMMARY:
Requires manufacturers and/or distributors of dietary supplements containing live microorganisms (commonly known as probiotics) to appropriately label the number and type of microorganisms included.
COMMENTS:
- Probiotic Uses. According to the World Health Organization, probiotics are live microorganisms that when administered in appropriate amounts confer health benefits to the person or animal that consumed them. Products containing probiotics can be classified into three different categories, food (i.e. yogurt), drugs, and dietary supplements. Each different classification is regulated differently under federal law. This bill specifically applies only to those marketed and classified as dietary supplements. Currently, labeling practices for these products are only regulated at the federal level by the Food and Drug Administration (FDA).
- Federal Regulation of Dietary Supplements. Manufacturers, under federal law are responsible for ensuring that their products are both safe in the manner they are intended to be used as well as that the representations or claims made about their products are not false or misleading. Dietary supplements are required by federal law to list ingredients by weight. The FDA actively exercises authority over New Dietary Ingredients (NDI), including probiotic ingredients, applications that are submitted. Applications that are denied by the FDA include those proposing microorganisms with insufficient scientific evidence for safety. NDIs are also more likely to be denied if a particular microorganism included is not well characterized, meaning the functions are not well-established. Under current practices, only the genus and species of the microorganism are required to be listed as ingredients, strains are inconsistently listed and thus inconsistently identified as NDIs.
- Challenges in Probiotic Labeling. Measuring microorganisms by weight inevitably counts both live and dead microorganisms, giving no indication of the viability of the product. Thus, quantifying the number of live microorganisms, using methods such as colony forming units (CFU), is critical for transparency and product integrity, and is inherent to the very definition of a probiotic. In September 2018, the FDA issued a draft guidance, entitled "Policy Regarding Quantitative Labeling of Dietary Supplements Containing Live Microbials: Guidance for Industry", allowing CFUs to be listed together with the current requirement of weight per serving. Listing both metrics can pose additional challenges for consumers. The number of live microorganisms is expected to vary between batches, and batches should be tested to estimate live quantities, and final products should be formulated accordingly based on estimated targets. In practice, this means that each batch may have different number of microorganisms-to-weight ratios, requiring the manufacturer to print unique labels for every batch. The FDA is currently reviewing these issues in regard to clarifying labeling practices
- Live Microorganism Strains. Under federal law, any health benefit claims made about dietary supplements and their ingredients must not be misleading. Manufacturers of probiotic containing dietary supplements use different strains of microorganisms. Within a single species of microorganism, different strains have different reported health functions. Thus, to ensure consumers are getting the expected health benefit, it is critical that products are labeled appropriately with strain-level information otherwise it is impossible for consumers to compare the content of over the counter probiotics across manufacturers. Importantly, there are also safety concerns with consumers not knowing the particular strain of a probiotic. A 2010 review in the journal Gut Microbiomes finds that in the field of probiotics, shows that some strains that are utilized have less evidence for safety than others. Inconsistencies in dietary supplement labeling, largely the lack of specific strain identification, has made it difficult to conclusively identify probiotics that may be detrimental to human health. Requiring strain identification in product labeling can help identify unsafe products and allow consumers to make informed decisions on their probiotics.
According to the Author:
According to the author, probiotics manufacturers currently label live microorganisms using varying levels of specificity. However, because different microbial strains can have different effects, strain-level identification is important for substantiating claims and ensuring the integrity of a probiotic. In addition, federal law mandates that probiotics are quantified by weight, which provides little information regarding the quantity of live microorganisms in a product. The author states that it is important that consumers know exactly which and how many microorganisms they're consuming. The author concludes we cannot expect manufacturers to label their products inconsistently without providing standardization. This bill addresses both of these issues.
Arguments in Support:
According to the author, probiotics manufacturers which operate under limited federal guidance, currently label live microorganisms using varying levels of specificity. However, because different microbial strains can have different effects, strain-level identification is important for substantiating claims and ensuring the integrity of a probiotic. In addition, federal law mandates that probiotics are quantified by weight, which provides little information regarding the quantity of live microorganisms in a product. The author states that it is important that consumers know exactly which and how many microorganisms they're consuming. The author concludes we cannot expect manufacturers to label their products inconsistently without providing standardization. This bill addresses both of these issues.
Arguments in Opposition:
According to the American Herbal Products Association and the Council for Responsible Nutrition, the proposed requirements conflict with the FDA's current regulations on probiotic labeling, thereby creating inconsistent labeling requirements that will result in unnecessary compliance challenges, despite the fact that it appears the FDA is moving in the right direction on this issue.
FISCAL COMMENTS:
According to the Assembly Appropriations Committee, any impact to the California Department of Public Health to enforce the labeling requirement is expected to be minor and absorbable (Food Safety Fund).
VOTES:
ASM HEALTH: 14-1-0
YES: Wood, Mayes, Aguiar-Curry, Bigelow, Bonta, Burke, Carrillo, Flora, Limón, McCarty, Nazarian, Ramos, Rodriguez, Santiago
NO: Waldron
ASM APPROPRIATIONS: 17-0-1
YES: Gonzalez, Bigelow, Bonta, Brough, Calderon, Carrillo, Chau, Diep, Eggman, Fong, Gabriel, McCarty, Maienschein, Obernolte, Petrie-Norris, Quirk, Robert Rivas
ABS, ABST OR NV: Bloom
UPDATED:
VERSION: March 27, 2019
CONSULTANT: Marissa Kraynak / HEALTH / (916) 319-2097 FN: 0000189
Date of Hearing: April 10, 2019
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
ABPCA Bill Id:AB 1178
Author:(Quirk) – As Amended Ver:March 27, 2019
Policy Committee: | Health | Vote: | 14 - 1 |
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires manufacturers and/or distributors of dietary supplements containing live microorganisms (commonly known as probiotics) to appropriately label the number and type of microorganisms included.
FISCAL EFFECT:
Any impact to the California Department of Public Health to enforce the labeling requirement is expected to be minor and absorbable (Food Safety Fund).
COMMENTS:
- Purpose. According to the author, this bill is necessary to ensure consumers are able to understand the number and type of live microorganisms contained in probiotic products. Different microbial strains can have different effects, and the author believes consumers deserve complete and standardized information about the microbial quality of probiotic products.
- Background. According to the World Health Organization, probiotics are live microorganisms that, when administered in appropriate amounts, confer health benefits to the person or animal that consumed them. Products containing probiotics can be classified into three different categories: food (i.e. yogurt), drugs and dietary supplements. Each classification is regulated differently under federal law. The FDA has issued draft guidance last year on labeling, but has not adopted regulations on the matter.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: April 2, 2019
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 1178
Author:Quirk – As Amended Ver:March 27, 2019
SUBJECT: Dietary supplements: labeling: live microorganisms.
SUMMARY: Requires manufacturers and/or distributors of dietary supplements containing live microorganisms (commonly known as probiotics) to appropriately label the number and type of microorganisms included. Specifically, this bill:
- Requires, by January 1, 2022, probiotic labels to include the following:
- The genus, species, and strains of each live microorganism in the dietary supplement; and,
- The total estimated quantity of all live microorganisms in the dietary supplement at the end of its shelf life.
- Specifies that the provisions in this bill do not limit the rights, remedies, or duties otherwise applicable by law.
- Authorizes implementation of these provisions to the extent permitted by federal law.
EXISTING LAW:
- Establishes the Department of Public Health (DPH) to among other functions administer and enforce the Sherman Food, Drug, and Cosmetic Law (Sherman Law) which among other provisions, regulates the packaging and labeling of dietary supplements.
- Requires under Sherman Law that dietary supplements to be labeled clearly as dietary supplements and contain labeling as required by federal law.
- Requires that any product regulated under Sherman Law must follow good manufacturing practice standard, adopted by the federal government.
- Establishes the federal Food and Drug Administration (FDA) which among other functions regulates the packaging and labeling requirements of dietary supplements according to the Dietary Supplement Health and Education Act of 1994 (DSHEA).
- Defines, under federal law, a “dietary supplement” as any product taken by mouth that contains a “dietary ingredient” including vitamins, minerals, amino acids, herbs, botanicals, enzymes, or other substances that can be used to supplement an individual’s diet.
- Requires, under federal law, Dietary supplements to list the ingredients in descending order by weight; and dietary supplement labels to not be misleading; and, preparation and packaging of dietary supplements to follow the guidelines of good manufacturing practices (GMP).
- Requires the FDA to regulate products containing live microorganisms by their intended use as follows:
- When live microorganisms are added to a conventional food product to add to the nutrition, that product is regulated as a food product;
- When live microorganisms are used to cure, mitigate, treat, or prevent a disease that product is regulated as a drug and FDA approval is required before marketing and selling the product; and,
- When live microorganisms are added to a product to supplement the user’s diet and the product to which they are being added is not a conventional food product, the product is regulated as a dietary supplement.
FISCAL EFFECT: This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, probiotics manufacturers which operate under limited federal guidance, currently label live microorganisms using varying levels of specificity. However, because different microbial strains can have different effects, strain-level identification is important for substantiating claims and ensuring the integrity of a probiotic. In addition, federal law mandates that probiotics are quantified by weight, which provides little information regarding the quantity of live microorganisms in a product. The author states that it is important that consumers know exactly which and how many microorganisms they're consuming. The author concludes we cannot expect manufacturers to label their products inconsistently without providing standardization. This bill addresses both of these issues.
- BACKGROUND. According to the World Health Organization, probiotics are live microorganisms that when administered in appropriate amounts confer health benefits to the person or animal that consumed them. Products containing probiotics can be classified into three different categories, food (i.e. yogurt), drugs, and dietary supplements. Each different classification is regulated differently under federal law.
This bill specifically applies only to those marketed and classified as dietary supplements. Currently, labeling practices for these products are only regulated at the federal level.
- Federal Regulation of Dietary Supplements. Dietary supplement regulations are established federally under DSHEA. DSHEA prohibits supplements that pose a substantial risk of injury and authorizes the FDA to implement current GMP guidelines. DSHEA delegates responsibilities regarding the safety and efficacy of dietary supplements to both manufacturers and the FDA.
Manufacturers are responsible for ensuring that their products are both safe in the manner they are intended to be used as well as that the representations or claims made about their products are not false or misleading. Manufacturers do not have to report specific evidence for these claims to the FDA or any other entity if the live microorganism was established prior to DSHEA or is already generally recognized as safe. For new dietary ingredients (NDI) that have been added to products after DSHEA was passed in October 1994, however, manufacturers must notify the FDA about the ingredient and show reasonable evidence for why the new ingredient is expected to be safe for consumers.
The FDA actively exercises authority over NDI applications that are submitted. Applications that are denied by the FDA include those proposing microorganisms with insufficient scientific evidence for safety. NDIs are also more likely to be denied if a particular microorganism included is not well characterized, meaning the functions are not well-established. Under current practices, only the genus and species of the microorganism are required to be listed as ingredients, strains are inconsistently listed and thus inconsistently identified as NDIs.
Dietary supplements, including those containing probiotics, are required by federal law to list ingredients by weight. A 2018 report in Journal of America Medical Association entitled “Probiotic Safety- No Guarantees” reports that the FDA inspected 656 facilities that produce dietary supplements and found violations in more than 50% of the inspected facilities, most commonly failing to establish identity, purity, strength, or composition of their final product. A number of peer reviewed studies have also found commercial probiotics to contain strains of probiotics that were not listed on their labels.
- Challenges in Probiotic Labeling. Over the counter (OTC) probiotics are required to list their ingredients by weight. Measuring microorganisms by weight inevitably counts both live and dead microorganisms, giving no indication of the viability of the product. Thus, quantifying the number of live microorganisms, using methods such as colony forming units (CFU), is critical for transparency and product integrity, and is inherent to the very definition of a probiotic. In September 2018, the FDA issued a draft guidance, entitled “Policy Regarding Quantitative Labeling of Dietary Supplements Containing Live Microbials: Guidance for Industry”, allowing CFUs to be listed together with the current requirement of weight per serving.
Listing both metrics can pose additional challenges for consumers. The number of live microorganisms is expected to vary between batches, and batches should be tested to estimate live quantities, and final products should be formulated accordingly based on estimated targets. In practice, this means that each batch may have different number of microorganisms-to-weight ratios, requiring the manufacturer to print unique labels for every batch. The FDA is currently reviewing these issues in regard to clarifying labeling practices.
- Live Microorganism Strains. Under federal law, any health benefit claims made about dietary supplements and their ingredients must not be misleading. Manufacturers of probiotic containing dietary supplements use different strains of microorganisms. Within a single species of microorganism, different strains have different reported health functions. Thus, to ensure consumers are getting the expected health benefit, it is critical that products are labeled appropriately with strain-level information otherwise it is impossible for consumers to compare the content of OTC probiotics across manufacturers.
Importantly, there are also safety concerns with consumers not knowing the particular strain of a probiotic. A 2010 review in the journal Gut Microbiomes entitled “Current Level of Consensus on Probiotic Science” finds that in the field of probiotics, shows that some strains that are utilized have less evidence for safety than others. Preliminary studies have found isolated cases of infections associated with microorganisms contained in dietary supplements. Inconsistencies in dietary supplement labeling, largely the lack of specific strain identification, has made it difficult to conclusively identify probiotics that may be detrimental to human health. Requiring strain identification in product labeling can help identify unsafe products and allow consumers to make informed decisions on their probiotics.
- Final Considerations. According to the 2012 National Health Interview Survey, probiotics are the third most commonly used dietary supplements behind vitamins and minerals. Between 2007 and 2012, the use of dietary supplements containing probiotics experienced a four-fold increase in and the U.S. market is expected to reach $6.5 billion by 2023. Thus, implementing more consistent and appropriate labeling practices can ensure that probiotics, as a growing industry, are safe and not misleading in their health benefit claims.
- SUPPORT. According to the California Medical Association (CMA), one of the biggest challenges to assessing the safety of dietary supplements containing live microorganisms is that there are no current guidelines to how the live microorganisms should be labeled. Manufacturers commonly identify microorganisms by only their genus and species, without a strain. As a result, it is difficult for consumers to compare products between different manufacturers.
REGISTERED SUPPORT / OPPOSITION:
Support
California Medical Association
International Scientific Association for Probiotics and Prebiotics
Opposition
Council for Responsible Nutrition
Analysis Prepared by: Marissa Kraynak / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):